51. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297: 353–356. 52. LaFerla FM, Oddo S (2005) Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11: 170–176. 53. Kaur D, Andersen JK (2002) Ironing out Parkinson’s disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell 1: 17–21. 54. Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 5: 535–551. 55. Kakhlon O, Cabantchik ZI (2002) The labile iron pool: characterization, measurement, and participation in cellular processess. Free Radical Biology and Medicine 33: 1037–1046. 56. Kalaria RN, Sromek SM, Grahovac I, Harik SI (1992) Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer’s disease. Brain Res 585: 87–93. 57. Testa U, Petrini M, Quaranta MT, Pelosi-Testa E, Mastroberardino G, et al. (1989) Iron up-modulates the expression of transferrin receptors during monocyte-macrophage maturation. J Biol Chem 264: 13181–13187. 58. Theil EC (1990) Regulation of ferritin and transferrin receptor mRNAs. J Biol Chem 265: 4771–4774. 59. Henderson RJ, Connor JR: Iron’s involvement in the molecular mechanisms of Alzheimer’s disease pathogenesis; Neuronal and Vascular Plasticity: Elucidating Basic cellular Mechansims for Future Therapeutic Discovery. ordrecht/Detroit, Kluwer, 2003. 60. Thompson KJ, Shoham S, Connor JR (2001) Iron and neurodegenerative disorders. Brain Res Bull 55: 155–164. 61. Bouton C, Drapier JC (2003) Iron regulatory proteins as NO signal transducers. Sci STKE 2003: e17. 62. Hentze MW, Kuhn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A 93: 8175–8182. 63. Iwai K, Drake SK, Wehr NB, Weissman AM, LaVaute T, et al. (1998) Iron- dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci U S A 95: 4924–4928. 64. Klausner RD, Rouault TA, Harford JB (1993) Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72: 19–28. 65. Todorich BM, Connor JR (2004) Redox metals in Alzheimer’s disease. Ann N Y Acad Sci 1012: 171–178. Gadd153 Mediates 27-OHC-Induced AD Pathology 66. Wallander ML, Leibold EA, Eisenstein RS (2006) Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim Biophys Acta 1763: 668–689. 67. Schipper HM (2004) Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev 3: 265–301. 68. Fleming J, Joshi JG (1987) Ferritin: isolation of aluminum-ferritin complex from brain. Proc Natl Acad Sci U S A 84: 7866–7870. 69. Seiser C, Posch M, Thompson N, Kuhn LC (1995) Effect of transcription inhibitors on the iron-dependent degradation of transferrin receptor mRNA. J Biol Chem 270: 29400–29406. 70. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27: 209–214. 71. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, et al. (1998) Abnormal localization of iron regulatory protein in Alzheimer’s disease. Brain Res 788: 232–236. 72. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer’s disease. Trends Neurosci 18: 172–176. 73. Stadtman ER (1992) Protein oxidation and aging. Science 257: 1220–1224. 74. Kim E, Giri SN, Pessah IN (1995) Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol 130: 57–66. 75. Chao CC, Hu S (1994) Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 16: 172–179. 76. Louis JC, Magal E, Takayama S, Varon S (1993) CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 259: 689–692. 77. Hascalovici JR, Vaya J, Khatib S, Holcroft CA, Zukor H, Song W, Arvanitakis Z, Bennett DA, Schipper HM (2009) Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1. J Neurochem 110: 1241–53. 78. Vaya J, Schipper HM (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 102: 1727–37. 79. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR (2008) High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 106: 475–85. PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e26420